|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV03311983X |
| 003 |
DE-627 |
| 005 |
20230623224646.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
180603s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.earlhumdev.2013.02.008
|2 doi
|
| 028 |
5 |
2 |
|a GBVA2013012000013.pica
|
| 035 |
|
|
|a (DE-627)ELV03311983X
|
| 035 |
|
|
|a (ELSEVIER)S0378-3782(13)00038-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 082 |
0 |
4 |
|a 618.3/005
|q OCLC
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 084 |
|
|
|a 44.45
|2 bkl
|
| 100 |
1 |
|
|a Zhao, Min
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Placental expression of VEGF is increased in pregnancies with hydatidiform mole: Possible association with developing very early onset preeclampsia
|
| 264 |
|
1 |
|c 2013
|
| 300 |
|
|
|a 6
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a Hydatidiform mole is an abnormal pregnancy with over-proliferation of the placenta, which causes the dysfunction of placenta. Although more than 80% of hydatidiform moles are benign with good outcome, hydatidiform moles are associated with developing very early onset preeclampsia. However the association between hydatidiform mole and very early onset preeclampsia is unclear. Preeclampsia is associated with altered levels of angiogenic factors, like vascular endothelial growth factor (VEGF) and soluble endoglin.
|
| 700 |
1 |
|
|a Yin, Yongxiang
|4 oth
|
| 700 |
1 |
|
|a Guo, Fang
|4 oth
|
| 700 |
1 |
|
|a Wang, Jiajun
|4 oth
|
| 700 |
1 |
|
|a Wang, Ke
|4 oth
|
| 700 |
1 |
|
|a Chen, Qi
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier Science
|a Abdel-Aziz, Tarek Ezzat ELSEVIER
|t Study of serum leptin in well differentiated thyroid carcinoma: Correlation with patient and tumor characteristics
|d 2014
|g Amsterdam [u.a.]
|w (DE-627)ELV022803173
|
| 773 |
1 |
8 |
|g volume:89
|g year:2013
|g number:8
|g pages:583-588
|g extent:6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.earlhumdev.2013.02.008
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 44.45
|j Immunologie
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 89
|j 2013
|e 8
|h 583-588
|g 6
|
| 953 |
|
|
|2 045F
|a 610
|